Literature DB >> 11341650

Combined therapy with interferon and ribavirin in chronic hepatitis C does not affect serum quasispecies diversity.

S Sookoian1, G Castaño, B Frider, J Cello, R Campos, D Flichman.   

Abstract

Our aim was to investigate if interferon plus ribavirin has any effect on serum HCV quasispecies distribution and the relationship between diversity of HCV quasispecies and treatment response. In all, 21 patients were treated with interferon plus ribavirin for 48 weeks. The presence of HCV quasispecies was determined in serum samples at baseline and at the fourth week of treatment by SSCP analysis of the hypervariable region. SSCP pattern was defined as single or multiple band. A single band was found in six patients and multiple bands in nine. No significant difference was found between SSCP pattern in pretreatment samples and response to the therapy. In none of the patients were observed changes in number of SSCP bands between samples taken at baseline and in the fourth week of the therapy. In conclusion, the complexity of HCV quasispecies before the therapy was not related to treatment response; combined therapy did not affect serum HCV quasispecies.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11341650     DOI: 10.1023/a:1010718213584

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  17 in total

1.  Evaluation of two simplified methods for genotyping hepatitis C virus.

Authors:  R U Khan; C Y Tong; S Bloom; I T Gilmore; C H Toh; P H Bolton-Maggs; N J Beeching; C A Hart
Journal:  J Med Virol       Date:  1997-05       Impact factor: 2.327

2.  Influence of viral quasispecies on effectiveness of interferon therapy in chronic hepatitis C patients.

Authors:  Y Kanazawa; N Hayashi; E Mita; T Li; H Hagiwara; A Kasahara; H Fusamoto; T Kamada
Journal:  Hepatology       Date:  1994-11       Impact factor: 17.425

3.  Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C. Meta-analysis of individual patient data from European centers.

Authors:  S W Schalm; B E Hansen; L Chemello; A Bellobuono; J T Brouwer; O Weiland; L Cavalletto; R Schvarcz; G Ideo; A Alberti
Journal:  J Hepatol       Date:  1997-05       Impact factor: 25.083

4.  Selection of hepatitis C virus quasispecies during interferon treatment.

Authors:  I Sakuma; N Enomoto; M Kurosaki; F Marumo; C Sato
Journal:  Arch Virol       Date:  1996       Impact factor: 2.574

5.  Detection of hepatitis C virus quasispecies heterogeneity by single-strand conformational polymorphism.

Authors:  R P Gonález-Peralta
Journal:  Methods Mol Med       Date:  1999

6.  Effects of the ribavirin-interferon alpha combination on cultured peripheral blood mononuclear cells from chronic hepatitis C patients.

Authors:  J Martín; S Navas; J A Quiroga; M Pardo; V Carreño
Journal:  Cytokine       Date:  1998-08       Impact factor: 3.861

7.  Effect of ribavirin on virus load and quasispecies distribution in patients infected with hepatitis C virus.

Authors:  J H Lee; M von Wagner; W K Roth; G Teuber; C Sarrazin; S Zeuzem
Journal:  J Hepatol       Date:  1998-07       Impact factor: 25.083

8.  Clinical outcomes after transfusion-associated hepatitis C.

Authors:  M J Tong; N S el-Farra; A R Reikes; R L Co
Journal:  N Engl J Med       Date:  1995-06-01       Impact factor: 91.245

9.  Hepatitis C virus (HCV) circulates as a population of different but closely related genomes: quasispecies nature of HCV genome distribution.

Authors:  M Martell; J I Esteban; J Quer; J Genescà; A Weiner; R Esteban; J Guardia; J Gómez
Journal:  J Virol       Date:  1992-05       Impact factor: 5.103

10.  Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group.

Authors:  J G McHutchison; S C Gordon; E R Schiff; M L Shiffman; W M Lee; V K Rustgi; Z D Goodman; M H Ling; S Cort; J K Albrecht
Journal:  N Engl J Med       Date:  1998-11-19       Impact factor: 91.245

View more
  3 in total

1.  Quasispecies as predictive response factors for antiviral treatment in patients with chronic hepatitis C.

Authors:  Javier Salmerón; Paloma Muñoz De Rueda; Angela Ruiz-Extremera; Jorge Casado; Carlos Huertas; Maria Del Carmen Bernal; Luis Rodríguez; Angel Palacios
Journal:  Dig Dis Sci       Date:  2006-05       Impact factor: 3.199

2.  Mechanisms of action of interferon and ribavirin in chronic hepatitis C: Summary of a workshop.

Authors:  Raymond T Chung; Michael Gale; Stephen J Polyak; Stanley M Lemon; T Jake Liang; Jay H Hoofnagle
Journal:  Hepatology       Date:  2008-01       Impact factor: 17.425

3.  Extinction of hepatitis C virus by ribavirin in hepatoma cells involves lethal mutagenesis.

Authors:  Ana M Ortega-Prieto; Julie Sheldon; Ana Grande-Pérez; Héctor Tejero; Josep Gregori; Josep Quer; Juan I Esteban; Esteban Domingo; Celia Perales
Journal:  PLoS One       Date:  2013-08-16       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.